Ocrelizumab is a novel humanized anti-CD20 antibody used for treatment of relapsing remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and eventually vaccinate patients with multiple sclerosis before new disease modifying therapy initiation. However, there are not any specific recommendations about vaccinal immunity reassessment after ocrelizumab injection. We describe the case of a patient who loss varicella zoster vaccinal immunity after the first ocrelizumab infusion. It is advisable to reassess vaccinal immunity to isolate non-immune patients and to adopt suitable preventive measures, including close contacts vaccination and avoidance of contacts with active infection.

Ocrelizumab是一种新型人源化抗CD20抗体，用于治疗复发性和原发性进行性多发性硬化症，具有炎症活性。指南建议评估疫苗接种状态，并在开始新的疾病改良疗法之前最终为多发性硬化症患者接种疫苗。但是，对于注射ocrelizumab后的疫苗免疫重新评估，没有任何具体建议。我们描述了第一次ocrelizumab输注后水痘带状疱疹疫苗免疫力下降的患者。建议重新评估疫苗免疫力，以隔离非免疫患者，并采取适当的预防措施，包括紧密接触疫苗接种和避免接触主动感染。